TheraRadar
← Back
Data updated: Jun 28, 2026

CHIA TAI TIANQING

Generics
OncologyRespiratoryImmunology Execution: Needs Improvement

CHIA TAI TIANQING is a generic drug manufacturer focused on Oncology, Respiratory, Immunology.

2020
Since
3
Drugs
-
Trials
0
New Drugs (2yr)

CHIA TAI TIANQING at a Glance

  • Growing R&D activity with 59 trials in last 2 years
  • Fast trial execution (19 months median completion)

CHIA TAI TIANQING's Key Drugs

CHIA TAI TIANQING's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

CHIA TAI TIANQING's Recent FDA Approvals

New NDA/BLA approvals for CHIA TAI TIANQING over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

CHIA TAI TIANQING's Therapeutic Areas

CHIA TAI TIANQING's approved drugs and pipeline span 5 therapeutic areas, led by Oncology and Respiratory. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Oncology 75%
2 drugs Phase 3: 26 Phase 2: 34 Phase 1: 72
Respiratory 10%
0 drugs Phase 3: 3 Phase 2: 9 Phase 1: 4
Immunology 5%
0 drugs Phase 2: 6 Phase 1: 6
Metabolic 5%
0 drugs Phase 3: 2 Phase 2: 1 Phase 1: 6
Infectious Disease 5%
0 drugs Phase 2: 5 Phase 1: 6

CHIA TAI TIANQING's Top Competitors

CHIA TAI TIANQING's closest competitors by therapeutic-area and drug-target overlap include GSK, Merck, and Johnson & Johnson. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

GSK big-pharma
Respiratory, Infectious Disease, Oncology, Immunology, Metabolic
Merck big-pharma
Oncology, Infectious Disease, Metabolic, Respiratory
Johnson & Johnson big-pharma
Oncology, Immunology, Infectious Disease, Metabolic
Sanofi big-pharma
Metabolic, Oncology, Infectious Disease, Immunology
AstraZeneca big-pharma
Oncology, Respiratory, Metabolic, Immunology

CHIA TAI TIANQING Pipeline Snapshot

CHIA TAI TIANQING has 180 active clinical programs from ClinicalTrials.gov — 31 Phase 3, 55 Phase 2 and 94 Phase 1.

31
Phase 3
55
Phase 2
94
Phase 1

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • Top drug revenue breakdown
  • • Drug-level revenue analysis

Trial Catalysts

  • • Oncology pipeline focus
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison

Execution Intelligence

  • • Phase 3: 2/23 completed
  • • Speed: 19 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges